Support our Foundation of Myology project
1722 news items
French study identifies prognostic markers for interstitial lung disease associated with anti-synthase syndrome
On 04/02/2026
Conducted in seven reference or competence centres in north-eastern France, the TYPASS retrospective study included 132 adults with antisynthetase syndrome and interstitial lung disease: 39%…
Positive results from the Phase III SAPPHIRE trial with apitegromab in SMA
On 02/02/2026
Apitegromab is a human monoclonal antibody that selectively inhibits myostatin activation to improve muscle function. Its efficacy was evaluated at one year in the Phase…
Feedback on inflammatory myositis in the African population of Martinique
On 30/01/2026
Clinicians in Martinique report on their experience in the field of inflammatory myopathies occurring in the Caribbean population of African origin: the records of 174…
Evrysdi, reimbursed for presymptomatic SMA
On 29/01/2026
According to the publication in the Official Journal of 13 January 2026, the conditions for reimbursement of Evrysdi (Risdiplam) in oral solution form have been…
Is rituximab useful in ocular myasthenia gravis?
On 29/01/2026
Chinese clinicians report encouraging results regarding the use of rituximab, an anti-CD20 monoclonal antibody, in forms of ocular myasthenia gravis: their pilot study involved 9…
“Michel Fardeau, a life under the microscope”: testimony from a pioneer in myology
On 28/01/2026
The French Society of Myology (SFM) has published « Michel Fardeau, a life under the microscope », a beautiful book (in French) dedicated to the founding father…
An unprecedented paediatric case of myopathy linked to the HMGCR gene
On 28/01/2026
HMGCR is an enzyme involved in the metabolism of cholesterol and other metabolites. Until now, it was best known in connection with autoimmune necrotising myopathy…
A rare form of myosinopathy now better understood
On 27/01/2026
Researchers at the Institute of Myology* compiled clinical and genetic data from 13 patients who were found to have pathologic variants of the MYH2 gene:…
A comprehensive study of a series of patients with SLONM
On 26/01/2026
Italian clinicians analysed the clinical and biological data from a large series of cases of sporadic late-onset nemaline myopathy (SLONM): they added their own cases…
The utility of the national Pompe disease registry in understanding causes of death and comorbidities
On 26/01/2026
The French Pompe disease registry, which includes 200 patients, is an unrivalled source of clinical and biological data that provides a better understanding of the…
A comparative analysis of long-read sequencing techniques in two neuromuscular diseases
On 22/01/2026
In collaboration with their Japanese colleagues, researchers from the Myology Institute* compared the diagnostic use of new sequencing technologies in the context of a growing…
M&M’s – Muscle Monday Seminar – 26 Jan. – Dr Metodi Metodiev (France)
On 21/01/2026
Mitochondrial diseases: pathogenesis and cure 26 January 2026 from noon to 1pm (Paris time) Dr Metodi METODIEV (Institut Imagine, Paris) Invited by Marc Bitoun More information on the…
A first step towards the possibility of administering gene therapy in subjects already immune to AAV
On 21/01/2026
American researchers in Indiana have studied ways to overcome the obstacle posed by the presence of neutralising antibodies in patients who need to undergo viral…
Is methylprednisolone effective in treating cognitive impairment in DMD?
On 20/01/2026
Chinese researchers studied the potentially positive effects of intraperitoneal corticosteroid injection in a mouse model of Duchenne muscular dystrophy (DMD): the working hypothesis was that…
Cardiac complications observed in rats treated with microdystrophin
On 19/01/2026
French researchers, in collaboration with the Généthon laboratory, report the results of a study conducted on rats with Duchenne muscular dystrophy (DMD) treated with microdystrophin…
A new protocol for treatment with high-dose nusinersen arrives in Europe
On 16/01/2026
While nusinersen is currently administered at a dose of 12 mg intrathecally, a new treatment device with higher doses (50 mg and 28 mg) has…
The French model for multidisciplinary team meetings in SMA
On 14/01/2026
With the arrival of three innovative treatments (Spinraza, Zolgensma and Evrysdi), multidisciplinary team meetings (MTM) were set up in France in 2017 and then rolled…
DMD: dystrophin deficiency also affects vascular cells
On 13/01/2026
While vascular damage is suspected in Duchenne muscular dystrophy (DMD), recent studies show that dystrophin deficiency alters the plasticity of vascular smooth muscle cells. These…
A French study sheds light on the progression of CMT 4C
On 12/01/2026
Conducted over 20 years (2003–2023), this study involved 103 patients with Charcot-Marie-Tooth disease linked to the SH3TC2 gene (CMT 4C) who were monitored in 27…
GC101 gene therapy shows encouraging results in type II and III SMA in nine patients
On 09/01/2026
While Zolgensma gene therapy is only indicated for children weighing less than 21 kg with type I SMN1-related proximal spinal muscular atrophy (SMA) or who…
